PMID- 24053345
OWN - NLM
STAT- MEDLINE
DCOM- 20140423
LR  - 20211021
IS  - 1744-8360 (Electronic)
IS  - 1473-7175 (Print)
IS  - 1473-7175 (Linking)
VI  - 13
IP  - 9
DP  - 2013 Sep
TI  - Cellular targets and mechanistic strategies of remyelination-promoting IgMs as 
      part of the naturally occurring autoantibody repertoire.
PG  - 1017-29
LID - 10.1586/14737175.2013.835601 [doi]
AB  - Immunoglobulins with germline sequences occur in invertebrates and vertebrates 
      and are named naturally occurring autoantibodies (NAbs). NAbs may target foreign 
      antigens, self- or altered self-components and are part of the normal 
      immunoglobulin repertoire. Accumulating evidence indicates that naturally 
      occurring antibodies can act as systemic surveillance molecules, which tag, 
      damaged or stressed cells, invading pathogens and toxic cellular debris for 
      elimination by the immune system. In addition to acting as detecting molecules, 
      certain types of NAbs actively signal in different cell types with a broad range 
      of responses from induction of apoptosis in cancer cells to stimulation of 
      remyelination in glial cells. This review emphasizes functions and 
      characteristics of NAbs with focus on remyelination-promoting mouse and human 
      antibodies. Human remyelination-promoting NAbs are potential therapeutics to 
      combat a wide spectrum of disease processes including demyelinating diseases like 
      multiple sclerosis. We will highlight the identified glycosphingolipid (SL) 
      antigens of polyreactive remyelination-promoting antibodies and their proposed 
      mechanism(s) of action. The nature of the identified antigens suggests a lipid 
      raft-based mechanism for remyelination-promoting antibodies with SLs as most 
      essential raft components. However, accumulating evidence also suggests 
      involvement of other antigens in stimulation of remyelination, which will be 
      discussed in the text.
FAU - Watzlawik, Jens O
AU  - Watzlawik JO
AD  - Departments of Neurology and Immunology, Mayo Clinic, College of Medicine, 200 
      First Street, S.W., Rochester, MN 55905, USA.
FAU - Wootla, Bharath
AU  - Wootla B
FAU - Painter, Meghan M
AU  - Painter MM
FAU - Warrington, Arthur E
AU  - Warrington AE
FAU - Rodriguez, Moses
AU  - Rodriguez M
LA  - eng
GR  - CA 1060A/CA/NCI NIH HHS/United States
GR  - UL1TR000135/TR/NCATS NIH HHS/United States
GR  - UL1 TR000135/TR/NCATS NIH HHS/United States
GR  - R01 NS048357/NS/NINDS NIH HHS/United States
GR  - R21 NS073684/NS/NINDS NIH HHS/United States
GR  - R01 GM092993/GM/NIGMS NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Expert Rev Neurother
JT  - Expert review of neurotherapeutics
JID - 101129944
RN  - 0 (Autoantibodies)
RN  - 0 (Autoantigens)
RN  - 0 (Immunoglobulin M)
SB  - IM
MH  - Animals
MH  - Autoantibodies/*immunology
MH  - Autoantigens/immunology
MH  - Demyelinating Diseases/*immunology
MH  - Humans
MH  - Immunoglobulin M/*immunology
MH  - Mice
MH  - Myelin Sheath/*immunology
PMC - PMC3909667
MID - NIHMS546628
EDAT- 2013/09/24 06:00
MHDA- 2014/04/24 06:00
PMCR- 2014/09/01
CRDT- 2013/09/24 06:00
PHST- 2013/09/24 06:00 [entrez]
PHST- 2013/09/24 06:00 [pubmed]
PHST- 2014/04/24 06:00 [medline]
PHST- 2014/09/01 00:00 [pmc-release]
AID - 10.1586/14737175.2013.835601 [doi]
PST - ppublish
SO  - Expert Rev Neurother. 2013 Sep;13(9):1017-29. doi: 10.1586/14737175.2013.835601.